RSS Feeds
Search

Companies

Companies

No results found for given criteria.
Please try to put more general criteria into your selection.

Related Reports

Market Research Reports provided by reports.iptechex.com
The Market Outlook for Neurodegenerative Diseases
Sep 2010 - 137 pages - $3,835
Gilenya (Fingolimod), Laquinimod and Cladribine - Impact on the Multiple Sclerosis (MS) Treatment Landscape
Mar 2011 - 6 pages - $500
Multiple Sclerosis Drug Discoveries: what the future holds
Oct 2010 - 102 pages - $2,265
CNS Drug Discoveries: Multiple Sclerosis Chapter
Aug 2008 - 128 pages - $1,040
Multiple Sclerosis Market Forecast
Dec 2009 - $15,200
Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth
Oct 2011 - 145 pages - $3,500
Clinical Trial Recruitment in Central Nervous System Disorders - Highest Number of Patients were Recruited for Clinical Trials in Schizophrenia
Sep 2011 - 97 pages - $3,500
Epidemiology: Multiple Sclerosis - Improved diagnosis and survival are important drivers behind the current high levels of multiple sclerosis prevalence
Mar 2011 - 50 pages - $5,700
Clinical Trial Recruitment in Autoimmune Disorders-Average Patient Recruitment Per Trial has Continued to Decline Over the Past Decade
Sep 2011 - 95 pages - $3,500
Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010
Nov 2011 - 230 pages - $3,500
More Related Market Research Reports >>>

Your selection

Therapeutic target
Central Nervous System del
Neurodegenerative disorders del
Multiple sclerosis del
Geographic location
Africa del
Egypt del

Browse By

Industry sector
Academic/Research
Animal health
Biotechnology
Diagnostic
Drug delivery
Drug discovery
Medical device
Non-profit org./Government
Pharmaceutical
Research tools
Service

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us